甲磺酸萘莫司他在ICU高出血风险患者连续性血液净化中的应用  

Application of Nafamostat Mesylate in Continuous Blood Purification for ICU Patients with High Bleeding Risk

作　　者：任彦文 向淑麟[2] REN Yanwen;XIANG Shulin(Graduate School of Youjiang Medical University for Nationalities,Baise 533000,Guangxi,China;Department of Critical Care Medicine of the People's Hospital of Guangxi Zhuang Autonomous Region/Guangxi Academy of Medical Sciences,Nanning 530021,Guangxi,China)

机构地区：[1]右江民族医学院研究生学院,广西百色533000 [2]广西壮族自治区人民医院/广西医学科学院重症医学科,广西南宁530021

出　　处：《医学信息》2025年第4期182-187,共6页Journal of Medical Information

基　　金：广西医疗卫生适宜技术开发与推广应用项目(编号:S2022016)。

摘　　要：抗凝药物在连续性血液净化(CBP)中起着重要作用,目前常用的传统抗凝药物包括肝素、低分子肝素、枸橼酸等,这些药物都有相应的并发症及禁忌症。ICU中,当面对高出血风险患者,尤其是同时合并肝功能不全、高乳酸血症等情况时,上述抗凝药物或均存在局限性,而甲磺酸萘莫司他(Nafamostat Mesilate)具有安全、有效等特点,可作为高出血风险患者进行连续性血液净化的抗凝首选。但是,萘莫司他使用的监测指标及其优势、局限等仍需更多临床试验验证。本文主要总结高出血风险患者使用萘莫司他作为连续性血液净化治疗抗凝药物的应用,为临床决策等方面提供参考依据。Anticoagulant drugs play an important role in continuous blood purification(CBP).At present,the commonly used traditional anticoagulant drugs include heparin,low molecular weight heparin,citric acid,etc.These drugs have corresponding complications and contraindications.In ICU,in the face of patients with high risk of bleeding,especially with liver dysfunction and hyperlactacidemia,the above anticoagulant drugs may have limitations.Nafamostat mesilate has the characteristics of safety and effectiveness,and can be used as the first choice of anticoagulation for continuous blood purification in patients with high risk of bleeding.However,the monitoring indicators used by nafamostat and its advantages and limitations still need more clinical trials to verify.This article mainly summarizes the application of nafamostat as an anticoagulant drug for continuous blood purification in patients with high bleeding risk,and provides reference for clinical decision-making.

关 键 词：甲磺酸萘莫司他 抗凝 高出血风险 连续性血液净化 

分 类 号：R459.5[医药卫生—治疗学]